G3T Therapeutics products

Using today`s technologies we have the capability to measure every molecule in the blood that can be measured. We perform the following measurements and combine the results with deep, quantitative phenotypic data:

We deployed non-invasive imaging in nearly all of our ~8,000 patients. These proprietary images are analyzed in a central core laboratory to quantify factors relating to disease states of interest, including:

All drugs targeting cardiovascular disease currently on the market work by lowering cholesterol levels. G3T identified and genetically validated an entirely novel biological mechanism and potential drug target that treats both cardiovascular disease, as well as non-alcoholic fatty liver disease. This is an unprecedented clinical opportunity. This genetically validated asset is currently in preclinical development.